This should move soon. The company is committed to announcing AT LEAST TWO partnerships soon. They have even said "by the end of this year" which means probably in the next 4 weeks! November 19 the CEO said "We are BEYOND NEGOTIATING FINANCIAL TERMS with AT LEAST 2 of the prospects..."
They have also announced that there will be an additional two INDs filed by the end of the year. Dr.Wijatyk spoke about the second generation CTLA-4 IND and the two new INDs as follows...
"Today, I am pleased to announce that we have filed an IND for our next generation CTLA-4 antibody. We have briefly described our next-generation CTLA-4, AGEN1181, in our last earnings call. This molecule, we believe, will have both potential efficacy and safety advantages relative to competitor molecules, including: one, enhanced potency through increased potential for T cell priming, while we also achieve Treg depletion. This is a very challenging and unique attribute that we have been able to achieve with this molecule; two, broader benefit to a wider patient population, including the approximately 40% of patients who are unlikely to respond to first-generation CTLA-4 therapies due to a genetic predisposition; and third, improved safety through Fc engineering to avoid common side effects of first-generation CTLA-4 antibody and enhanced therapeutic potential to enable broader range of dosing options, all of which have been achieved with 1181 based on the data that we have generated in preclinical models so far.
As I said earlier, additionally, we are on track to file INDs for 2 of our first-in-class bispecific antibodies this year."
These are very important best-in-class and first-in-class drugs!
"The refusal of the real is the number one dogma of our time" Rene Girard
